HydroCision

HydroCision, Inc. is a privately held medical device company based in Billerica, Massachusetts, in the United States. The company is focused on the commercialization of its proprietary FluidJet technology, a method of delivering a pressurized, high-velocity jet of sterile saline to selectively resect and remove targeted tissue in a minimally invasive manner. According to the company, this non-thermal water energy approach is intended to enable new minimally invasive surgical approaches and improve patient outcomes. HydroCision's core technological proposition is tissue differentiation: the high-velocity, non-thermal saline stream cuts and simultaneously aspirates tissue without the need for external suction. The company has built a portfolio of single-use handpiece instruments designed to cut and remove tissue faster and with higher precision than other surgical modalities, aiming to enhance both clinical and economic outcomes across multiple fields of surgery. The company's product family includes TenJet for tenotomy, SpineJet for discectomy, and AlloJet for allograft procedures. TenJet is positioned for the treatment of chronic tendinopathy, including in the elbow, hip, and shoulder, and the company has stated that TenJet's tissue selectivity allows removal of pathologic tendon tissue while preserving adjacent healthy tendon, which may enable quicker and less painful post-procedure rehabilitation. HydroCision has also licensed its technology to partners; notably, it announced a global licensing agreement with PROCEPT BioRobotics in 2019 relating to its proprietary pump cartridge technology, and in 2021 it congratulated PROCEPT BioRobotics on its initial public offering, noting that HydroCision had licensed its technology to that company. HydroCision describes itself as a pioneer in high-velocity, heat-free FluidJet technology for surgical resection. Its stated mission is to improve surgical outcomes by enabling novel minimally invasive solutions that meet unmet clinical needs across various medical specialties. The company is guided by a management team and board of directors, with Rick Lytle serving as President and Chief Executive Officer, alongside other named leaders in sales, finance and administration, and spine and business development. As a privately held company, HydroCision does not disclose public financial statements. Its activities center on research and development, patent protection of its selective tissue removal methods, clinical data generation through registries, and strategic licensing agreements. The company continues to pursue applications of its FluidJet platform across multiple clinical areas.

HydroCision, Inc. is a privately held medical device company based in Billerica, Massachusetts, United States. The company was founded to commercialize a proprietary method of delivering and utilizing a pressurized, high-velocity jet of sterile saline to selectively resect and remove targeted tissue in a minimally invasive manner. This technology, which HydroCision brands as FluidJet, uses non-thermal water energy to cut and simultaneously aspirate tissue without external suction. HydroCision describes itself as a pioneer in high-velocity, heat-free FluidJet technology for surgical resection. Over time, the company established a portfolio of single-use handpiece instruments designed to cut and remove tissue faster and with higher precision than other surgical modalities, with the goal of enhancing clinical and economic outcomes in multiple fields of surgery. Its product family includes TenJet for tenotomy, SpineJet for discectomy, and AlloJet for allograft procedures. A significant development in the company's history was its strategic licensing activity. On March 26, 2019, HydroCision announced a global licensing agreement with PROCEPT BioRobotics, providing access to its proprietary pump cartridge technology. In November 2021, HydroCision publicly congratulated PROCEPT BioRobotics on the closing of its upsized initial public offering, noting that HydroCision had licensed its technology to PROCEPT and that such strategic agreements, alongside its own research and development efforts, were uncovering the potential of its technology to address unmet needs across multiple clinical areas. HydroCision has also pursued patent protection for its innovations. On June 7, 2022, the company announced that the U.S. Patent and Trademark Office had issued patent No. 11,278,305, titled 'Selective Tissue Removal Treatment Device,' for its TenJet device. HydroCision stated that TenJet is believed to be the first patented device allowing for the targeted removal of tendon tissue, and that its tissue selectivity feature allows removal of pathologic tendon tissue while preserving adjacent healthy tendon, enabling quicker and less painful post-procedure rehabilitation. In January 2023, HydroCision announced the TenJet Patient Registry, intended to systematically gather and analyze data to understand how effective TenJet is in treating chronic tendinopathy in the elbow, hip, and shoulder. The company also engages in educational and clinical activities, such as the TenJet Sports Medicine Physicians Group, designed for physicians beginning to offer TenJet as a treatment option in their practices. HydroCision is led by a management team that includes Rick Lytle as President and Chief Executive Officer, Jill Martin as National Sales Director, Thomas Abert as Head of Finance and Administration, and Paul Kowalski as Head of Spine & Business Development. The company states that its mission and vision are driven by its management team and guided by an expert Board of Directors. As a privately held company, HydroCision does not publicly disclose detailed financial results.

• HydroCision announced a global licensing agreement with PROCEPT BioRobotics, providing access to its proprietary pump cartridge technology.

• HydroCision congratulated PROCEPT BioRobotics on its upsized initial public offering, noting its technology had been licensed to PROCEPT.

• U.S. Patent No. 11,278,305, titled 'Selective Tissue Removal Treatment Device,' was issued for the TenJet device.

• HydroCision announced the TenJet Patient Registry to study TenJet's effectiveness in treating chronic tendinopathy in the elbow, hip, and shoulder.

Pioneer in high-velocity, heat-free FluidJet technology for minimally invasive surgical resection, with a focus on tissue-selective soft tissue removal for spine and orthopedic applications.

• TenJet for Tenotomy

  A single-use handpiece instrument for tenotomy procedures, designed for targeted removal of tendon tissue while preserving adjacent healthy tendon, used in treating chronic tendinopathy in the elbow, hip, and shoulder.

• SpineJet for Discectomy

  A single-use handpiece instrument for discectomy procedures, applying FluidJet technology for minimally invasive spine surgery.

• AlloJet for Allograft

  A single-use handpiece instrument for allograft procedures, part of HydroCision's FluidJet-assisted soft tissue resection portfolio.

1. 1Minimally Invasive Surgery Technology | HydroCisionhydrocision.com
2. 2Our Story & More About Our Company | HydroCisionhydrocision.com
3. 3HydroCision Newshydrocision.com
4. 4HydroCision Eventshydrocision.com
5. 5HydroCision (United States) - Wikidatawikidata.org